CEO Remedica Group

Μιχαήλ Νεοπτολέμου

Dr Michael Neoptolemou is a seasoned academic and a PhD graduate whose illustrious career spans the public, higher education and corporate sectors. He has been a member of the top management of Remedica since 2014. He joined the board of directors in 2017 and currently serves as its chairman. In July 2019, he was appointed as the company’s Group Chief Executive Officer. Under his leadership, Remedica has increased its Research and Development (R&D) activities, invested in the development of new pharmaceutical products to its portfolio while maximising the revenue and profitability.